Aphria Signs Supply Agreement with MBLL to Supply Up to 2.7 Million Grams of Cannabis to the Manitoba Adult-Use Market

Aphria Inc. (“Aphria” or the”Company“) (TSX: APH and US OTC: APHQF) today announced that it has signed a Supply Agreement (the”Agreement“) together with the Manitoba Liquor and Lotteries Corporation (“MBLL“) to supply a portfolio of high quality, branded cannabis and cannabis derivative products for sale in Manitoba’s adult-use market.

Aphria Inc. (CNW Group/Aphria Inc.)

“We are thrilled to finalize this Agreement together with the MBLL,” said Jakob Ripshtein, Chief Commercial Officer at Aphria. “Our broad portfolio of adult-use brands and products has been especially developed to meet the needs of distinct consumer segments, whether new to cannabis or long-time aficionados. We are excited that Manitoba’s adult customers will have the chance to find our thoughtfully developed brands and products.”

Under the conditions of the Agreement, the Company will provide around 2.7 million grams of cannabis and cannabis derivative products in the first year of the agreement, including both Ontario and BC dried flower, pre-rolls and cannabis oils. The wide range of products will be available for sale at licensed retailers throughout the province. It is anticipated that additional products now being developed by Aphria, such as vapes and edibles, will also be made available in Manitoba when authorized for sale under the Cannabis Act.

“This partnership with Manitoba represents yet another significant step towards the future as we continue to create history across Canada in the march towards lawful sales this fall” said Vic Neufeld, Chief Executive Officer at Aphria. “With our annual production capacity reaching 255,000 kg in early 2019 and our recently declared partnership with Great North Distributors, we’re incredibly ready to meet the expected demand in Manitoba and across Canada.”

We Have a Good Thing Growing

About Aphria

Aphria is a major global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Headquartered in Leamington, Ontario — the greenhouse capital of Canada — Aphria has been setting the benchmark for its low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is dedicated to bringing breakthrough innovation to the global cannabis industry. The Company’s portfolio of brands is grounded in expertly-researched consumer insights developed to meet the needs of each consumer segment. Rooted in our founders’ multi-generational experience in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in over 10 countries across 5 continents.

For more information, see: aphria.ca

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are included in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements in this news release include, but are not limited to, statements with regard to internal expectations, estimated margins, expectations with respect to real production volumes, expectations of imports to Provincial Liquor Control Boards expectations for future growing capacity and costs, the completion of any capital project or expansions, and expectations with regard to future production expenses. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse business events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory issues; the ability of Aphria to execute its business plans; competition; crop failure; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to put undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they’re placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those expected.

Forward-looking statements included in this news release are expressly qualified by this cautionary statement.

For media queries please contact: Andrew Swartz, Director of Communications, andrew.swartz@aphria.com, 416-268-7099Copyright CNW Group 2018

Released at Fri, 29 Jun 2018 11:04:32 +0000

Posted in: News

Comments are closed.